TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04604678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin at 1500 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Naltrexone at 4.5 mg/day (LDN)
Study: NCT00533741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Adjuvant; administered with SARS-CoV vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Adjuvant; administered with SARS-CoV vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Description: Adjuvant; administered with SARS-CoV vaccine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline for injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV
Description: Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV
Description: Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV
Description: Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV
Description: Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
Study: NCT04390750

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Partner-Assisted Intervention
Description: Tailored teaching and coaching
Study: NCT05330338

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Genetic analyses: whole genome sequencing
Description: Identification of de novo genetic variants using a whole genome sequencing (WGS) approach in the context of familial trios analysis
Study: NCT05135949

Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: Satisfaction, Disabilities of the Shoulder, Arm and Hand

Intervention type: OTHER
Intervention: Patient Reported Outcomes
Description: Satisfaction, Disabilities of the Shoulder, Arm and Hand

Intervention type: OTHER
Intervention: Strength Test
Description: Handheld dynamometer to measure tricep extension

Intervention type: OTHER
Intervention: Strength Test
Description: Handheld dynamometer to measure tricep extension
Study: NCT05779397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo RAD-GT
Description: Non-contact infrared thermometry device
Study: NCT04903808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allium Sativum Oil
Description: Garlic oil Captain Company (CAP-PHARM)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral Tri-Oxide Aggregate
Description: ProRoot MTA, Dentsply
Study: NCT06151145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in usual care will be emailed monthly educational modules with information on maintaining weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SELF
Description: The SELF group will receive a wireless smart body weight scale and wearable physical activity tracker, and text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP
Description: The STEP intervention consists of 4 steps that are progressive and based on response to treatment. Step 1: Digital health intervention. The first step will be the digital health intervention as described under SELF. Step 2: Monthly, in-person counseling. Participants who move to Step 2 will be provided with monthly, in-person counseling. Step 3: Twice per month counseling. Step 3 will be twice-monthly counseling, spaced at every other week. Step 4: Meal replacements. Participants will be prescribed a partial meal replacement program.
Study: NCT06225635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezerosu(monolayer tablet)
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezerosu(monolayer tablet)
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezerosu(double layer tablet)
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezerosu(double layer tablet)
Description: Ezetimibe 10mg, Rosuvastatin calcium 20.8mg(20mg as Rosuvastatin)
Study: NCT06270433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toludesvenlafaxine hydrochloride sustained-release tablets
Description: 80 mg or 120 mg or 160 mg orally once daily dosing for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desvenlafaxine succinate sustained-release tablets
Description: 50 mg orally once daily dosing for 8 weeks
Study: NCT05280587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Rehabilitation
Description: Specific rehabilitation for balance disorder using the robotic platform
Study: NCT05350878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Intervention
Description: Virtual and in-person implementation support
Study: NCT05898386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour and Lifestyle Changes in Urinary Incontinence
Description: The women included in the second stage were given a pre-test before the training program. Training program included behavioral and lifestyle changes in coping with urinary incontinence~After the training program, the women applied behavior and lifestyle changes for 3 months.~3 home visits, 3 phone calls and 3 follow-ups were made.
Study: NCT06147635

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micro-encapsulated granules of tributyrin (intervention)
Description: Three times daily 4 grams of micro-encapsulated granules of tributyrin, for a maximum of 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Micro-encapsulated granules of sunflower oil (placebo)
Description: Three times daily 4 grams of micro-encapsulated granules of sunflower oil, for a maximum of 14 days
Study: NCT04680403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise paired with coaching on behavior change techniques over 12 weeks (3 weekly sessions) and will have monthly phone follow-ups and clinic follow-ups after 3 and 6 months.
Study: NCT05092633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrew
Description: Application of laser on miniscrew

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniscrew
Description: Application of laser on miniscrew
Study: NCT04841551

Intervention type: DRUG
Group type: OTHER
Intervention: Kybella Flanks
Description: 10 subjects will be treated with Kybella in the flanks
Study: NCT04081454

Intervention type: BEHAVIORAL
Intervention: Workshop
Description: one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain

Intervention type: BEHAVIORAL
Intervention: Workshop
Description: one-day (6 hour) program to help children and their parents or caregivers learn how to better manage chronic pain
Study: NCT05365425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Policosanol
Description: policosanol 10mg
Study: NCT04081454

Intervention type: BEHAVIORAL
Intervention: Education
Description: The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.

Intervention type: BEHAVIORAL
Intervention: Education
Description: The parent program includes psychoeducation regarding pain in the context of adolescent development, didactic and vignette-based practice of an adaptive parent communication response style (i.e., reflective listening), and concrete tools for setting up behavior plans to scaffold an adolescent's return to function for school, sleep, daily activities, and exercise. All parents are provided with a take-home workbook inclusive of neuroscience and psychoeducational materials as well as a list of resources to further solidify the information they learned.
Study: NCT06493812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia lata
Description: This intervention involves the harvesting of fascia lata from the thigh and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left thigh, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Temporal fascia
Description: This intervention involves the harvesting of temporal muscle fascia from the temporal region of the head and its use in reconstructing the skull base defect following endoscopic endonasal surgery for sellar region pathology. The graft is extracted from the left temporal region, and standard reconstruction techniques are employed to ensure optimal healing and functionality of the skull base. Postoperative monitoring includes assessments of donor site pain, incidence of complications, and overall recovery using standardized measures.
Study: NCT04065152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec
Study: NCT05604833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation Exercises
Description: In the research, data will be collected with the Descriptive Information Form and Pittsburgh Sleep Quality Index (PUKI). Statistical analysis of the data obtained as a result of the research will be made in the IBM SPSS25 program. This study was planned because it is thought that making progressive muscle relaxation exercises (PKGE) in patients with poor sleep quality who receive hemodialysis treatment will be effective in increasing sleep quality, since it is easy to learn, can be done anywhere, and has no side effects.
Study: NCT04987658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Description: Olanzapine and Samidorphan taken once daily over a max period of 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Description: Olanzapine and Samidorphan taken once daily over a max period of 21 days
Study: NCT06348940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral activation
Description: Behavioral activation, an emerging psychological intervention approach, has potential in alleviating negative emotions among cancer patients. The intervention group underwent an eight-week behavioral activation program designed to promote engagement in meaningful activities that are physically and emotionally rewarding while reducing involvement in maladaptive emotional cycles.
Study: NCT05390359

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity and short-duration
Description: The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a high intensity current (3 mA), that will be applied for 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity and long-duration
Description: The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 squared pulses of a low intensity direct current (0.1 mA) during 90 seconds, with 3 seconds rests between pulses and 1 second of pulses ramp.~The total treatment time will be 366 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity, short-duration and 20 Hz
Description: The ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon.~The parameters will be 3 pulses of a high intensity compensated biphasic current (3 mA), during 3 seconds with 3 seconds rests between pulses and 1 second of pulses ramp. The alternating frequency will be of 20 Hz and the pulse width of 50 microseconds.~The current will be off on the first 348 seconds of the intervention approximately and the last 18 seconds it will be on. The total treatment time will be 366 seconds.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electrolysis
Description: The control ultrasound guided percutaneous electrolysis will be applied in the middle of the patellar tendon, without electrical stimulation during 366 seconds.
Study: NCT05785702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The anti-wandering system
Description: During the testing period, the system will promptly notify care staff if a participant enters unauthorized areas. A care staff will then go to that area and search for the participant. After the participant is found, care staff will reset the system, and then return the participant to a safe place.
Study: NCT05439434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire for Children Short Form
Description: administering the questionnaire twice, one week apart.
Study: NCT06485752

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tNIV 1 and Matrix-M Adjuvant
Description: tNIV will be administered as a single 0.5 mL IM injection Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tNIV 1 and Matrix-M Adjuvant
Description: tNIV will be administered as a single 0.5 mL IM injection Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tNIV 1 and Matrix-M Adjuvant
Description: tNIV will be administered as a single 0.5 mL IM injection Day 0
Study: NCT05784987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2, d0, Cycle 1\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome
Description: 20 mg/m2, d1, Cycle 1\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isophosphamide
Description: 1.33 g/m2, d1-3(Rescue with equal dose of mesperidine), Cycle 1\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 65 mg/m2, d1-3, Cycle 1\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X: Orelabrutinib
Description: MCD/BN2 subtype: BTK inhibitor-Orelabrutinib: 150 mg/d, d1-21, Cycle 2\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X: Chidamide
Description: EZB subtype: Chidamide: 20 mg/d, d1, d4, d8, d11, Cycle 2\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X: Penpulimab
Description: TP53 mutation - X: PD-1 monoclonal antibody - Penpulimab: 200mg/d, d0, Cycle 2\~4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X: Lenalidomide
Description: Other-X: Lenalidomide: 25mg/d, d1-10, Cycle 2\~4
Study: NCT06027190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Intervention Name and Specification~1. Transcranial magnetic stimulator (M-100 Ultimate, Yingzhi Technology Co., Ltd., China) .~2. 70-mm-diameter figure-of-eight coil (BY90A, Yingzhi Technology Co., Ltd., China). 3) Placebo coil (Magstim Company, Whitland, UK): the appearance and sound were consistent with the true coil, but no current stimulation was produced.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Placebo coil (Magstim Company, Whitland, UK):
Study: NCT06076486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix 200 mg tablets administered orally BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix placebo
Description: Elagolix placebo administered orally BID
Study: NCT06510647

Intervention type: OTHER
Intervention: Hormonal Therapy Agent
Description: With an endometriosis diagnosis in which hormonal therapy is indicated, patients who satisfy inclusion and exclusion criteria will be administered scientifically validated questionnaires at the time of the visit (time 0): Endometriosis Health Profile-30 and the Short Form Health Survey SF-12.~The second evaluation will be conducted 6 months later (time 1) along with a gynecological examination and gynecological ultrasound, and the same two questionnaires will be administered. Patients will be defined as non-responsive to medical therapy if their Endometriosis Health Profile 30 scores are equal to or higher at the time 1 visit compared to the enrollment visit at time 0.~Patients will then be re-evaluated 12 months (time 2) after the first visit with the same criteria, and the two questionnaires will be administered once more. Similarly, patients with EHP-30 scores equal to or higher than the previous control at time 1 will be defined as non-responsive to medical therapy.

Intervention type: OTHER
Intervention: Hormonal Therapy Agent
Description: With an endometriosis diagnosis in which hormonal therapy is indicated, patients who satisfy inclusion and exclusion criteria will be administered scientifically validated questionnaires at the time of the visit (time 0): Endometriosis Health Profile-30 and the Short Form Health Survey SF-12.~The second evaluation will be conducted 6 months later (time 1) along with a gynecological examination and gynecological ultrasound, and the same two questionnaires will be administered. Patients will be defined as non-responsive to medical therapy if their Endometriosis Health Profile 30 scores are equal to or higher at the time 1 visit compared to the enrollment visit at time 0.~Patients will then be re-evaluated 12 months (time 2) after the first visit with the same criteria, and the two questionnaires will be administered once more. Similarly, patients with EHP-30 scores equal to or higher than the previous control at time 1 will be defined as non-responsive to medical therapy.
Study: NCT05964803

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).

Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaires
Description: MLWH and control groups were asked to complete the following questionnaires: International Consultation on Incontinence Questionnaire - Male Lower Urinary Tract Symptoms (ICIQ-MLUTS), ICIQ-Short Form (ICIQ-SF), International Prostate Symptom Score (IPSS), King's Healthcare Questionnaire (KHQ), 8-item Overactive Bladder Questionnaire (OAB-V8), Urogenital Distress Inventory 6 and 7 (UDI 6 and UDI 7).
Study: NCT06428136

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clamshell exercises with Electrical Muscle Stimulation (CT + EMS)
Description: Side-lying clamshells: 3 sets of 10 repetitions per leg, 3 times per week Hip abduction with theraband: 3 sets of 10 repetitions per leg, 3 times per week Bridge with hip abduction: 3 sets of 10 repetitions per leg, 3 times per week~Electrical muscle stimulation:~Applied to the gluteus medius and minimus muscles for 20 minutes per session, 3 times per week Frequency and intensity adjusted to individual tolerance

Intervention type: OTHER
Group type: OTHER
Intervention: Conservative Treatment (CT)
Description: Stretching: Iliotibial band stretch: 30-second hold, 3 repetitions per leg, 2 times per day Quadriceps stretch: 30-second hold, 3 repetitions per leg, 2 times per day Hamstring stretch: 30-second hold, 3 repetitions per leg, 2 times per day
Study: NCT06270927

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: neuroimaging using MRI scanner

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: neuroimaging using MRI scanner

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: neuroimaging using CT scanner

Intervention type: DIAGNOSTIC_TEST
Intervention: CT
Description: neuroimaging using CT scanner
Study: NCT05908604

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Robot for madication management
Description: The effect of a robot in medication management for older people's home care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robot for madication management
Description: The effect of a robot in medication management for older people's home care
Study: NCT05010187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Motivational Interview (MI)
Description: Single-session, brief motivational interview.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral: Health Coaching (HC)
Description: Single-session health coaching.